title: FDG-PET in Lymphoma: Nuclear Medicine Perspective.
abstract: Positron emission tomography (PET) is a sectional molecular imaging procedure that allows evaluation of the metabolism at a molecular and cellular level. For a PET scan, the patient is injected with a radiotracer, such as (18)F-fluorodeoxyglucose (FDG). FDG PET-computed tomography has become an established modality for metabolic staging and plays an important role in the major steps of evaluation and treatment of most lymphoma subtypes, with significant impact in the initial staging, posttherapy evaluation, and suspect of relapse of disease. However, whenever the information of PET results is translated to changing treatment, especially in cases of further treatment, biopsy confirmation should always be made when possible.
authors.affiliation: Quanta - Diagnóstico Nuclear, R. Almirante Tamadaré, 1000, CEP 80045-170, Curitiba, Brazil; Heart Institute (InCor), University of São Paulo Medical School, Av. Dr Enéas de Carvalho Aguiar, 44 - 05403-900, São Paulo, Brazil.
authors.forename: Juliano Julio
authors.initials: JJ
authors.lastname: Cerci
authors.affiliation: Policlinico S. Orsola, University of Bologna, Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi, Via Massarenti, 9, 40138 Bologna, Italy.
authors.forename: Lucia
authors.initials: L
authors.lastname: Zanoni
authors.affiliation: Heart Institute (InCor), University of São Paulo Medical School, Av. Dr Enéas de Carvalho Aguiar, 44 - 05403-900, São Paulo, Brazil.
authors.forename: José C
authors.initials: JC
authors.lastname: Meneghetti
authors.affiliation: Policlinico S. Orsola, University of Bologna, Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi, Via Massarenti, 9, 40138 Bologna, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Fanti